Yuhan Corporation is a South Korean pharmaceutical company headquartered in Seoul. Founded in 1926, it develops, manufactures, and markets a wide range of prescription drugs, over-the-counter medicines, and health products. Its portfolio spans oncology, infectious diseases, cardiovascular conditions, and other therapeutic areas, with a focus on both domestic and international markets through partnerships and licensing agreements.
Also known as 유한양행 and Yuhan Yanghaeng.
Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.
CHRYSALIS-2 Phase1/1b (n=49): first-line atypical EGFR‑mutant NSCLC showed ORR 57%; 3‑yr OS 55%, 4‑yr OS 46%; 41% remained on treatment ≥2 years; safety consistent with prior reports.
